pentobarbital will lessen the level or outcome of tacrolimus by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital will reduce the extent or influence of vincristine liposomal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.

pentobarbital will lessen the level or effect of fedratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Effect of coadministering a powerful CYP3A4 inducer with fedratinib has not been studied.

pentobarbital will reduce the extent or effect of donepezil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Mysterious.

pentobarbital will lower the level or influence of pantoprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Mysterious.

pentobarbital will decrease the extent or result of fentanyl intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on to a reduce in fentanyl check here plasma concentrations, insufficient efficacy or, possibly, progress of the withdrawal syndrome in the affected individual who's got made Bodily dependence to fentanyl.

pentobarbital will minimize the extent or influence of eltrombopag by impacting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Keep track of.

Pentobarbital belongs to your barbiturate class of remedies and mainly will work primarily on the central anxious method (CNS).

pentobarbital will minimize the extent or impact of etravirine by influencing hepatic enzyme CYP2C9/ten metabolism. Use Caution/Watch.

pentobarbital will minimize the level or effect of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Mysterious.

pentobarbital will decrease the level or effect of theophylline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital decreases effects of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Coadministration of CYP3A4 inducers may reduce sufentanil concentrations and efficacy, probably precipitating withdrawal syndrome in sufferers who have created physical dependence to sufentanil. Discontinuation of concomitantly used CYP3A4 inducers may improve sufentanil plasma concentration.

pentobarbital will minimize the level or influence of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unfamiliar.

fentanyl intranasal and pentobarbital each improve sedation. Steer clear of or Use Alternate Drug. Restrict use to people for whom choice treatment method selections are insufficient